Judicial Watch, Inc. v. Food & Drug Admin.

Decision Date02 June 2006
Docket NumberNo. 05-5256.,05-5256.
Citation449 F.3d 141
PartiesJUDICIAL WATCH, INC., Appellant v. FOOD & DRUG ADMINISTRATION, et al., Appellees.
CourtU.S. Court of Appeals — District of Columbia Circuit

Appeal from the United States District Court for the District of Columbia (No. 00cv02973).

Meredith L. Di Liberto argued the cause for appellant. With her on the briefs was Paul J. Orfanedes.

Fred E. Haynes, Assistant U.S. Attorney, argued the cause for appellees Food & Drug Administration. With him on the brief were Kenneth L. Wainstein, U.S. Attorney, Michael J. Ryan, and Eric M. Blumberg, Deputy Chief Counsel, Food & Drug Administration. R. Craig Lawrence, Assistant U.S. Attorney, entered an appearance.

Nancy L. Buc, Kate C. Beardsley, and Carmen M. Shepard were on the brief for appellees Population Council, Inc. and Danco Laboratories, LLC.

Before: SENTELLE, HENDERSON and GARLAND, Circuit Judges.

Opinion for the Court filed by Circuit Judge SENTELLE.

SENTELLE, Circuit Judge.

Judicial Watch filed an action in the District Court for the District of Columbia, seeking enforcement of its Freedom of Information Act ("FOIA") request for all documents related to the Food and Drug Administration's ("FDA") approval of the drug mifepristone. It now appeals from the District Court's grant of summary judgment in favor of the FDA. Although we affirm the District Court's decision in a number of respects, because the FDA produced an inadequately detailed Vaughn index, we remand for further explanation of some of the index's entries.

I. Background

In September 2000, the FDA approved the drug mifepristone, better known as RU-486, for "medical abortion" during the first 49 days of pregnancy. Shortly thereafter, Judicial Watch submitted a FOIA request seeking all mifepristone-related documents in the FDA's possession. A few months later, having not received any documents, Judicial Watch sought to enforce its request in the District Court. The FDA requested a stay, which the District Court granted. The District Court ordered the FDA to produce all responsive documents by October 15, 2001.

After searching about 250,000 pages of information, the FDA disclosed over 9,000 relevant pages to Judicial Watch on a compact disc. It withheld over 4,000 other relevant documents in their entirety and parts of almost 2,000 more. The FDA compiled and produced a 1,500-page Vaughn index to summarize the withholdings. See Vaughn v. Rosen, 484 F.2d 820 (D.C.Cir.1973). In addition to its Vaughn index, the FDA filed a supporting declaration by Andrea Masciale, who supervised the FDA's search and review of documents for Judicial Watch's FOIA request. The Masciale declaration described the types of withheld information and defended the application of FOIA Exemptions 3, 4, 5, and 6 to that information. Danco Laboratories and Population Council—mifepristone's creator and manufacturer, respectively— intervened in the suit and filed two additional affidavits. The intervenors' affidavits supported the FDA's reasons for using Exemptions 4 and 6 to withhold information submitted to it during mifepristone's approval.

The FDA moved for summary judgment. Judicial Watch opposed the motion claiming the FDA performed an inadequate search, filed an inadequately detailed Vaughn index, and invoked several FOIA exemptions improperly. The District Court granted summary judgment for the FDA as to all matters. Judicial Watch now appeals the District Court's judgment as to the adequacy of the FDA's Vaughn index and the exemptions. We review de novo the District Court's grant of summary judgment. Chappell-Johnson v. Powell, 440 F.3d 484, 487 (D.C.Cir.2006).

II. Adequacy of the Vaughn Index

Judicial Watch primarily argues that the FDA has produced an inadequately detailed Vaughn index. In this section, we consider—and reject—the challenge in its broadest sense, as a facial attack on the structure of the Vaughn index. Although we find nothing structurally wrong with the FDA's submission, we find merit in the narrower part of Judicial Watch's adequacy argument, specifically that the FDA has vaguely described some individual documents. We defer discussion of the vagueness inquiries until Section III and its subsections dealing with each individual FOIA exemption at issue.

We also note at the outset that at oral argument Judicial Watch appeared to concede the untenable position of its challenge to the adequacy of detail regarding documents only partially withheld. The FDA argued—and we agree—that the released portion of each document satisfied its Vaughn burden by supplementing the corresponding Vaughn index entries. The released content of the documents served to illuminate the nature of the redacted material, often limited to names or addresses. Therefore, we find that the Vaughn index adequately described the partially withheld documents. As with the vagueness questions, we reserve until Section III our discussion of the merits of the FDA's decision to redact certain documents.

A. Functions of the Vaughn Index Requirement

Because of its unique evidentiary configuration, the typical FOIA case "distorts the traditional adversary nature of our legal system's form of dispute resolution." King v. U.S. Dep't of Justice, 830 F.2d 210 218 (D.C.Cir.1987) (quoting Vaughn, 484 F.2d at 824). When a party submits a FOIA request, it faces an "asymmetrical distribution of knowledge" where the agency alone possesses, reviews, discloses, and withholds the subject matter of the request. Id. The agency would therefore have a nearly impregnable defensive position save for the fact that the statute places the burden "on the agency to sustain its action." 5 U.S.C. § 552(a)(4)(B); see also Coastal States Gas Corp. v. Dep't of Energy, 617 F.2d 854, 861 (D.C.Cir. 1980) ("[T]he burden is on [the agency] to establish [its] right to withhold information from the public.").

Possessing both the burden of proof and all the evidence, the agency has the difficult obligation to justify its actions without compromising its original withholdings by disclosing too much information. The Vaughn index provides a way for the defending agency to do just that. By allowing the agency to provide descriptions of withheld documents, the index gives the court and the challenging party a measure of access without exposing the withheld information. The Vaughn index thereby also serves three important functions that help restore a healthy adversarial process:

[I]t forces the government to analyze carefully any material withheld, it enables the trial court to fulfill its duty of ruling on the applicability of the exemption, and it enables the adversary system to operate by giving the requester as much information as possible, on the basis of which he can present his case to the trial court.

Keys v. U.S. Dep't of Justice, 830 F.2d 337, 349 (D.C.Cir.1987) (internal quotation marks and citation omitted).

As past cases demonstrate, we focus on the functions of the Vaughn index, not the length of the document descriptions, as the touchstone of our analysis. See, e.g., Tax Analysts v. IRS, 410 F.3d 715, 719-20 (D.C.Cir.2005) (approving of Vaughn index with short descriptions because a combination of declarations and in camera review provided sufficient information for the court to review the claimed exemptions); Coastal States Gas, 617 F.2d at 861 (finding index with short descriptions inadequate because the supporting affidavits made "conclusory assertions of privilege"). Indeed, an agency may even submit other measures in combination with or in lieu of the index itself. Keys, 830 F.2d at 349 ("[I]t is the function, not the form, of the index that is important."). Among other things, the agency may submit supporting affidavits or seek in camera review of some or all of the documents "so long as they give the reviewing court a reasonable basis to evaluate the claim of privilege." Gallant v. NLRB, 26 F.3d 168, 172-73 (D.C.Cir.1994) (internal quotation marks and citation omitted). Any measure will adequately aid a court if it "provide[s] a relatively detailed justification, specifically identif[ies] the reasons why a particular exemption is relevant and correlat[es] those claims with the particular part of a withheld document to which they apply." Mead Data Cent., Inc. v. U.S. Dep't of Air Force, 566 F.2d 242, 251 (D.C.Cir.1977).

B. The Structure of the FDA's Index

In this case, the FDA took a combined approach. In response to Judicial Watch's FOIA request, it produced a 1,500-page Vaughn index and supplemented the index with the supporting declaration of Andrea Masciale. The index itself includes eleven categories, consisting of the following: (1) an index identification number; (2) the document's subject; (3) its date; (4) the author; (5) the recipient; (6) the total number of pages; (7) a category entitled "Attach Page"; (8) the disposition (that is, whether entirely or partially withheld); (9) the reason for being withheld; (10) the statutory authority for the withholding; and (11) the number of pages containing withheld information. Whereas the index takes a document-specific approach, the Masciale declaration steps through the claimed exemptions. It avoids discussion of individual documents, instead describing the kinds of information withheld and how they relate to the exemptions. The intervenors filed two additional affidavits. Each covers issues specific to the documents submitted to the FDA during mifepristone's approval process, including matters ranging from competition in the abortion market to confidentiality issues.

Judicial Watch argues that the FDA's index/affidavit combination fails because it does not treat each document individually. Context dictates our approach to the particularity required of agencies. An agency may not claim exemptions too broadly, thereby sweeping unprotected information within the statute's...

To continue reading

Request your trial
550 cases
  • James Madison Project v. Dep't of Justice
    • United States
    • U.S. District Court — District of Columbia
    • 22 Septiembre 2016
    ...process from revealing the very information the agency hopes to protect." ACLU II , 710 F.3d at 432 (citing Judicial Watch, Inc. v. FDA , 449 F.3d 141, 145–46 (D.C.Cir.2006) ). In this instance, lawyers asked lawyers for copies of the recipient lawyers' "[l]egal analyses" and " ‘damage’ or ......
  • Barnard v. Department of Homeland Sec.
    • United States
    • U.S. District Court — District of Columbia
    • 9 Febrero 2009
    ...individual which can be identified as applying to that individual.") (internal quotation and citation omitted); Judicial Watch, Inc. v. FDA, 449 F.3d 141, 152 (D.C.Cir.2006) (explaining that Exemption 6 protects "not just files, but also bits of personal information, such as names and addre......
  • Davidson v. U.S. Dep't of State
    • United States
    • U.S. District Court — District of Columbia
    • 2 Septiembre 2016
    ...News v. Samuels , 787 F.3d 1142, 1147 (D.C.Cir.2015) (brackets and internal quotation mark omitted) (quoting Judicial Watch, Inc. v. FDA , 449 F.3d 141, 152 (D.C.Cir.2006) ). "The information in the file ‘need not be intimate’ for the file to satisfy the standard, and the threshold for dete......
  • Gordon v. Courter
    • United States
    • U.S. District Court — District of Columbia
    • 31 Julio 2015
    ...of an agency policy and deliberative if it reflects the give-and-take of the consultative process." Judicial Watch, Inc. v. Food & Drug Admin., 449 F.3d 141, 151 (D.C.Cir.2006) (internal quotation marks and citation omitted). The agency withheld the following three categories of documents p......
  • Request a trial to view additional results
1 books & journal articles
  • "Whistle ... and you've got an audience.".
    • United States
    • Fordham Urban Law Journal Vol. 36 No. 4, June 2009
    • 1 Junio 2009
    ...GROUP ON UNAUTHORIZED DISCLOSURES OF CLASSIFIED INFORMATION, at B 1 (1982))). (27.) See generally Judicial Watch, Inc. v. FDA, 449 F.3d 141,151 (D.C. Cir. 2006) (recognizing that FOIA [section] 552(b)(5) incorporates the deliberative process privilege, which generally exempts from disclosur......
2 provisions
  • DC Register Vol 60, No 22, May 24, 2013 Pages 7226 to 7574
    • United States
    • District of Columbia Register
    • Invalid date
    ...why a particular exemption is applicable, sufficient to allow the decision-maker to evaluate the claim. Judicial Watch, Inc. v. FDA, 449 F.3d 141, 146 (D.C. Cir. In the case of the Appeal, DDOT has provided additional detail to support its position, including its claim of exemption. Therefo......
  • DC Register Vol 64, No 37, September 15, 2017 Pages 9025 to 9320
    • United States
    • District of Columbia Register
    • Invalid date
    ...upheld when necessary to protect the privacy interests of individuals to be safe from physical violence. See Judicial Watch, Inc. v. FDA, 449 F.3d 141 (D.C. Cir. 2006). Here, MPD has not asserted that the redaction of the business address is necessary to protect DISTRICT OF COLUMBIA REGISTE......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT